Inclusion Criteria:

          -  Patients must be willing to sign the protocol-specific written informed consent

          -  Patients with histologically confirmed intact primary cancer that is confirmed
             invasive carcinoma of the breast, with at least 1.0 cm residual disease as measured by
             mammography, ultrasound, or breast magnetic resonance imaging (MRI) after neoadjuvant
             anthracycline based chemotherapy

          -  Patients must have triple-negative breast cancer defined as estrogen receptor (ER) <
             10%; progesterone receptor (PR) < 10% by immunohistochemistry (IHC) and human
             epidermal growth factor receptor 2 (HER2) 0-1+ by IHC or 2+, fluorescence in situ
             hybridization (FISH) non-amplified

          -  Androgen receptor will be quantified using a Clinical Laboratory Improvement Act
             (CLIA)-compliant assay for AR on a biopsy specimen obtained prior to the start of
             treatment; AR-positivity is defined as >= 10% of nuclear staining

          -  Patient's disease state must be American Joint Committee on Cancer (AJCC) 7th edition
             stage I-III

          -  Patients must have a performance status of 0 - 1 on the Eastern Cooperative Oncology
             Group (ECOG) performance scale

          -  A negative serum or urine pregnancy test must be done within 72 hours before the first
             dose of the study medication for women of childbearing potential as per institutional
             guidelines; post-menopausal women (defines as no menses for at least 1 year) and
             surgically sterilized women are not required to undergo pregnancy test

          -  Men on study must use a condom if having sex with a pregnant woman

          -  Male patients and his female partner who is of childbearing potential must use 2
             acceptable methods of birth control (one of which must include a condom as a barrier
             method of contraception) starting at screening and continuing throughout the study
             period and for 3 months after final study drug administration

          -  Absolute neutrophil count >= to 1,500 /uL

          -  Platelets >= to 100,000 /uL

          -  Hemoglobin >= to 9 g/dL

          -  Creatinine clearance >= to 50 ml/min

          -  Total bilirubin =< to 1.5 X upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 X ULN

        Exclusion Criteria:

          -  Patients who have received any other previous antitumor therapies (other than
             anthracycline-based neoadjuvant chemotherapy for the current cancer event)

          -  Breast-feeding at screening or planning to become pregnant during the course of
             therapy

          -  Patients who have had major surgery within 21 days before cycle 1, day 1

          -  Patients with known history of hypersensitivity to paclitaxel that did not resolve
             with pre-medication

          -  Patients with left ventricular ejection fraction < 50% or 10% decrease from baseline
             on echocardiogram after anthracycline based chemotherapy

          -  Patients with gastrointestinal impairment that would affect the absorption of
             enzalutamide or previous history of colitis

          -  Subjects requiring daily corticosteroids, other than those given as premedication for
             the anthracycline-based chemotherapy

          -  Patients with known or suspected brain metastasis or active leptomeningeal disease

          -  History of seizure or any condition that may predispose to seizure (e.g., prior
             cortical stroke, significant brain trauma) at any time in the past; also, history of
             loss of consciousness or transient ischemic attack within 12 months of day 1 visit

          -  Myocardial infarction within 6 months before starting therapy, symptomatic congestive
             heart failure (New York Heart Association > class II), unstable angina, or unstable
             cardiac arrhythmia requiring medication